Efficacy and safety of drug-eluting stenting compared with bypass grafting in diabetic patients with multivessel and/or left main coronary artery disease

Figures

• 

  Figure 1. Flowchart for the study selection process.

• 

  Figure 2. Forest plots for major adverse cardiovascular events (MACE) (a), major adverse cardiac and cerebrovascular events (MACCE) (b), all-cause mortality (c), stroke (d), myocardial infarction (MI) (e), and repeat revascularization (f) in selected trials comparing percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG) in diabetic patients with coronary atherosclerotic heart disease.

• 

  Figure 3. Galbraith plots for major adverse cardiovascular events (MACE) (a), major adverse cardiac and cerebrovascular events (MACCE) (b), all-cause mortality (c), stroke (d), myocardial infarction (MI) (e), and repeat revascularization (f) in selected trials comparing percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG) in diabetic patients with coronary atherosclerotic heart disease.

• 

  Figure 4. Funnel plots for major adverse cardiovascular events (MACE) (a), major adverse cardiac and cerebrovascular events (MACCE) (b), all-cause mortality (c), stroke (d), myocardial infarction (MI) (e), and repeat revascularization (f) in selected trials comparing percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG) in diabetic patients with coronary atherosclerotic heart disease.

• 

  Figure 5. Egger’s publication bias plots for major adverse cardiovascular events (MACE) (a), major adverse cardiac and cerebrovascular events (MACCE) (b), all-cause mortality (c), stroke (d), myocardial infarction (MI) (e), and repeat revascularization (f) in selected trials comparing percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG) in diabetic patients with coronary atherosclerotic heart disease.